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1. Section 4.1, page 13, table 6, Class III: No Beneﬁt, recommendation #1. The sentence now reads, “Direct
thrombin dabigatran and factor Xa inhibitor rivaroxaban are not recommended in patients with AF and
end-stage CKD or on dialysis because of a lack of evidence from clinical trials regarding the balance of risks
and beneﬁts.” The sentence previously read, “Direct thrombin dabigatran and factor Xa inhibitor rivar-
oxaban are not recommended in patients with AF and end-stage CKD or on hemodialysis because of a lack
of evidence from clinical trials regarding the balance of risks and beneﬁts.”
2. Section 4.1, page 14, Class III: No Beneﬁt, recommendation #1. The sentence now reads, “The direct
thrombin inhibitor dabigatran and the factor Xa inhibitor rivaroxaban are not recommended in patients
with AF and end-stage CKD or on dialysis because of the lack of evidence from clinical trials regarding the
balance of risks and beneﬁts.” The sentence previously read, “The direct thrombin inhibitor dabigatran and
the factor Xa inhibitor rivaroxaban are not recommended in patients with AF and end-stage CKD or on
hemodialysis because of the lack of evidence from clinical trials regarding the balance of risks and beneﬁts.”
3. Section 4.1.1.1, page 15, column 2, paragraph 3. The following sentence has been deleted: “HEMORR2HAGES
includes the following variables: hepatic or renal disease, ethanol abuse, malignancy, older age, reduced
platelet count or function, rebleeding, hypertension, anemia, genetic factors, excessive fall risk, and stroke.”
4. Section 4.2.2.2, page 18, ﬁrst paragraph. The sentence now reads, “Dabigatran is the ﬁrst new oral anti-
coagulant approved by the U.S. Food and Drug Administration (FDA) to reduce the risk of stroke and
systemic embolism in patients with nonvalvular AF, and is a direct thrombin inhibitor.” The sentence
previously read, “Dabigatran was the ﬁrst new oral anticoagulant approved by the U.S. Food and Drug
Administration (FDA) for prevention of stroke in patients with AF and is a direct thrombin inhibitor.”
5. Section 4.2.2.2, page 19, ﬁgure 5, ARISTOTLE, Event Rate. The event rate now reads, “1.60 (1.41-1.80)”. The
event rate previously read, “1.80 (1.41-1.80)”.
6. Section 4.2.2.2, page 19, column 1, paragraph 3. The sentence now reads, “.(CHADS2 score 0 to 1 in 31.8%
of subjects, 2 in 35.6%, and >2 in 32.5%).” The sentence previously read, “.(CHADS2 score 0 to 1 in 31% of
subjects, 2 in 33%, and >2 in 32%).”
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23067. Section 4.2.2.2, page 19, column 2, fourth paragraph. The sentence now reads, “Rivaroxaban is the second
new oral anticoagulant approved by the FDA for reduction of risk of stroke and systemic embolism in
patients with nonvalvular AF and is a direct factor Xa inhibitor (Figure 4). It should be administered as a
single daily dose with the evening meal to ensure adequate absorption.” The sentence previously read,
“Rivaroxaban is the second new oral anticoagulant approved by the FDA and is a direct factor Xa inhibitor
(Figure 4). It can be administered as a single daily dose with a large meal to ensure adequate absorption.”
8. Section 4.2.2.2, page 20, column 1, second paragraph. The sentence now reads, “Apixaban is the third new
oral anticoagulant approved by the FDA for reduction of risk of stroke and systemic embolism with non-
valvular AF and is another direct factor Xa inhibitor (Figure 4).” The sentence previously read, “Apixaban is
the third new oral anticoagulant approved by the FDA and is another direct factor Xa inhibitor (Figure 4).”
9. Section 4.2.2.3, page 21, table 8, row 1, column 4, Rivaroxaban. The text now reads, “20 mg QD with the
evening meal”. The text previously read, “20 mg HS”.
10. Section 4.2.2.3, page 21, table 8, row 2, column 3, Dabigatran. The text now reads, “150 mg BID (CrCl >30
mL/min)”. The text previously read, “150 mg BID or 75 mg BID (CrCl >30 mL/min)”.
11. Section 4.2.2.3, page 21, table 8, row 2, column 4, Rivaroxaban. The text now reads, “15 mg QD with the
evening meal”. The text previously read, “15 mg HS”.
12. Section 4.2.2.3, page 21, table 8, row 3, column 4, Rivaroxaban. The text now reads, “15 mg QD with the
evening meal”. The text previously read, “15 mg HS”.
13. Section 4.2.2.3, page 21, table 8, footnote list. The footnotes now read “xDose-adjusted warfarin has been
used, but observational data on safety and efﬁcacy are conﬂicting. kModeling studies suggest that dabi-
gatran 75 mg BID might be safe for patients with CrCl 15–30 mL/min, but this has not been validated in a
prospective cohort. Some countries outside the United States use 110 mg BID.” The footnotes previously
read “xModeling studies suggest that dabigatran 75 mg BID might be safe for patients with CrCl 15–30
mL/min, but this has not been validated in a prospective cohort. Some countries outside the United States
use 110 mg BID. kDose-adjusted warfarin has been used, but observational data on safety and efﬁcacy are
conﬂicting.” Table symbols were adjusted accordingly.
14. Section4.2.2.3, page 21, table 8, abbreviation list. The text nowreads, “.CrCl, creatinine clearance; FDA,Food
and Drug Administration; INR, international normalized ratio; and QD, once daily.” The text previously read,
“.CrCl, creatinine clearance; HS, once daily in evening with food; and INR, international normalized ratio.”
15. Section 4.2.2.3, page 21, column 2, paragraph 2. The sentences now reads, “Absorbed dabigatran etexilate is
‘pumped’ back into the intestinal tract. Dabigatran also can cause dyspepsia. Coprescription with a proton
pump inhibitor can mildly reduce dabigatran peak concentrations; however, dose adjustment is not war-
ranted. Rivaroxaban and apixaban are contraindicated with drugs that are combined P-glycoprotein and
strong P450 3A4 (CYP3A4) inducers.” The sentences previously read, “Absorbed dabigatran etexilate is
‘pumped’ back into the intestinal tract; therefore, proton pump inhibitors may reduce absorption of
dabigatran. Rivaroxaban and apixaban are contraindicated with drugs that inhibit cytochrome P450 3A4
(CYP3A4), such as azole antimycotics, ritonavir, and clarithromycin.”
16. Section 5, page 25, table 10, column 1, Amiodarone. An asterisk (*) has been inserted after “Amiodarone”.
The accompanying footnote below reads, “*Multiple dosing schemes exist for the use of amiodarone.”
17. Section 6.1.3, page 31, table 12, Drug, Amiodarone. An asterisk (*) has been inserted after “Amiodarone”.
The accompanying footnote below reads, “Multiple dosing schemes exist for the use of amiodarone.”
18. Section 6.2.1.1, page 33, table 13, Exclude/Use With Caution, Dofetilide. Added Hypomagnesemia.
19. Section 6.2.1.1, page 33, table 13, Major Pharmacokinetic Drug Interactions, Dofetilide. The text now reads,
“Primary renal elimination involving glomerular ﬁltration and active tubular secretion: verapamil.” The
text previously read, “Metabolized by CYP3A: verapamil.”
20. Section 6.2.1.1, page 33, table 13, Exclude/Use With Caution, Sotalol. Added Hypomagnesemia.
21. Reference Section, page 47. Reference 7 was removed and replaced with references 7a and 7b.Now listed:
7a. Al-Khatib SM, Allen Lapointe N, Chatterjee R, et al. Treatment of Atrial Fibrillation. Comparative
Effectiveness Review 119. (Prepared by the Duke Evidence-based Practice Center under Contract
No. 290-2007-10066-I.) AHRQ Publication No.13-EHC095-EF. Rockville, MD: Agency for Health-
care Research and Quality; June 2013. Available at: http://www.effectivehealthcare.ahrq.gov/ehc/
products/358/1559/atrial-ﬁbrillation-report-130628.pdf. Accessed August 14, 2014.
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23077b. Lopes RD, Crowley MJ, Shah BR, et al. Stroke Prevention in Atrial Fibrillation. Comparative Effec-
tiveness Review No. 123. (Prepared by the Duke Evidence-based Practice Center under Contract No.
290-2007-10066-I.) AHRQ Publication No. 13-EHC113-EF. Rockville, MD: Agency for Healthcare
Research and Quality; August 2013. Available at: http://www.effectivehealthcare.ahrq.gov/ehc/
products/352/1668/stroke-atrial-ﬁbrillation-report-130821.pdf. Accessed August 14, 2014.
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7. Agency for Healthcare Research and Quality. Research protocol: treatment of atrial ﬁbrillation.
Available at: http://effectivehealthcare.ahrq.gov/ehc/products/358/946/AtrialFibrillationTreatment_
AmendedProtocol_20120530.pdf. 2012. Accessed May 23, 2014.22. Reference Section, page 51. Reference 239 was replaced with a new reference.
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ewall S, Cattaneo M, Collet JP, et al. Expert position paper on the use of proton pump inhibitors in
patients with cardiovascular disease and antithrombotic therapy. Eur Heart J. 2013 Jun;34(23):1708-13,
1713a-1713b. Epub 2013 Feb 20.
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idbuchel H, Verhamme P, Alings M, et al. European Heart Rhythm Association Practical Guide on the use
of new oral anticoagulants in patients with non-valvular atrial ﬁbrillation. Europace. 2013;15:625–51.http://dx.doi.org/10.1016/j.jacc.2014.04.005
